Nyxoah S.A. (NASDAQ:NYXH) is a medical technology company focused on developing and commercializing innovative solutions for the treatment of sleep apnea. The company is known for its Genio® system, a device designed to treat obstructive sleep apnea. As a player in the medical device industry, Nyxoah competes with other companies offering solutions for sleep disorders.
On May 13, 2025, Nyxoah is scheduled to release its quarterly earnings. Wall Street analysts estimate an earnings per share (EPS) of -$0.49, indicating that the company is not currently profitable. The projected revenue is approximately $1.64 million. Despite these figures, the company’s financial ratios provide a deeper insight into its financial health.
Nyxoah’s price-to-earnings (P/E) ratio is -3.37, reflecting its lack of profitability. The price-to-sales ratio is 41, meaning investors are paying $41 for every dollar of sales. This high ratio suggests that investors have high expectations for the company’s future growth. The enterprise value to sales ratio is slightly lower at 38.44, indicating the company’s market value relative to its sales.
The enterprise value to operating cash flow ratio is -3.58, further highlighting Nyxoah’s current lack of profitability. The earnings yield is -29.67%, showing negative earnings relative to its share price. However, the debt-to-equity ratio is 0.20, indicating a low level of debt compared to equity, which is a positive sign for the company’s financial stability.
Nyxoah’s current ratio is 4.56, suggesting a strong liquidity position. This means the company is well-equipped to cover its short-term liabilities. Despite the ongoing investigation by Pomerantz LLP into potential securities fraud, the company’s recent announcement of an Approvable Letter from the FDA for its Genio® system indicates progress in its regulatory journey, as highlighted by Access Newswire.
